Related Experiment Video
Updated: Mar 2, 2026

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
Published on: October 4, 2024
[New drugs for horses and production animals in 2016]
1Dr. Ilka Ute Emmerich, VETIDATA, Institut für Pharmakologie, Pharmazie und Toxikologie, Veterinärmedizinische Fakultät, Universität Leipzig, An den Tierkliniken 39, 04103 Leipzig,
Abstract:
In 2016, only one newly developed active pharmaceutical ingredient for horses and food-producing animals was released on the German market for veterinary drug products. The immunomodulator Pegbovigrastim is now available as an injection solution for cattle (Imrestor®). Four established veterinary active pharmaceutical ingredients are available for further species: the ectoparasitic Amitraz (Apitraz®) from the triazapentadiene group was additionally authorized for honeybees, the expectorant Bromhexine (Exflow® Vet) for chickens, turkeys and ducks and the macrolide antibiotic Gamithromycin (Zactran®) for pigs. The dopamine D2 receptor agonist Cabergolin (Velactis®) was released for dairy cattle. However, the authorization was suspended a few months after market introduction because of severe side effects. Additionally, one veterinary drug with a new combination of active ingredients as well as one active substance in mono-preparation have been launched on the market for horses and food producing animals.
More Related Videos
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Drug Products: Biologics, Biosimilars and Interchangeables
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Equivalents
Clinically Relevant Drug Product Specifications: Methods of Establishment

